HIV vaccine trial
Readers also engaged with a piece from last March about innovation, mRNA style.
The first participant was dosed, back then, in a Phase 1 clinical trial of HIV trimer mRNA vaccine candidate mRNA-1574.
The US trial was set to evaluate the safety and immunogenicity of three candidates, also exploring different dose levels, representing the second HIV vaccine trial initiated by Moderna this year, with another Phase 1 trial testing HIV vaccine antigens.
Photo credit: GettyImages/Luso